Literature DB >> 19243384

A2B5 cells from human glioblastoma have cancer stem cell properties.

Aurélie Tchoghandjian1, Nathalie Baeza, Carole Colin, Myriam Cayre, Philippe Metellus, Christophe Beclin, L'Houcine Ouafik, Dominique Figarella-Branger.   

Abstract

Glioblastomas, like other cancers, harbor small cell populations with the capability of sustaining tumor formation. These cells are referred to as cancer stem cells. We isolated cells expressing the surface marker A2B5 from three human glioblastomas (GBM) and showed that after grafting into nude mice, they generated dense and highly infiltrative tumors. Then, we extensively studied A2B5(+) cells isolated from 11 human GBM. These cells display neurosphere-like, self-renewal, asymmetrical cell division properties and have multipotency capability. Stereotactic xenografts of dissociated A2B5(+)-derived secondary spheres revealed that as few as 1000 cells produced a tumor. Moreover, flow cytometry characterization of A2B5(+)-derived spheres revealed three distinct populations of cells: A2B5(+)/CD133(+), A2B5(+)/CD133(-) and A2B5(-)/CD133(-), with striking proportion differences among GBM. Both A2B5(+)/CD133(+) and A2B5(+)/CD133(-) cell fractions displayed a high proliferative index, the potential to generate spheres and produced tumors in nude mice. Finally, we generated two green fluorescent protein-cell lines that display--after serum induction--distinct proliferative and migratory properties, and differ in their CD133 level of expression. Taken together, our results suggest that transformed A2B5(+) cells are crucial for the initiation and maintenance of GBM, although CD133 expression is more involved in determining the tumor's behavior.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19243384     DOI: 10.1111/j.1750-3639.2009.00269.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  71 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

Review 2.  Structures, biosynthesis, and functions of gangliosides--an overview.

Authors:  Robert K Yu; Yi-Tzang Tsai; Toshio Ariga; Makoto Yanagisawa
Journal:  J Oleo Sci       Date:  2011       Impact factor: 1.601

3.  Evidence for label-retaining tumour-initiating cells in human glioblastoma.

Authors:  Loic P Deleyrolle; Angus Harding; Kathleen Cato; Florian A Siebzehnrubl; Maryam Rahman; Hassan Azari; Sarah Olson; Brian Gabrielli; Geoffrey Osborne; Angelo Vescovi; Brent A Reynolds
Journal:  Brain       Date:  2011-04-22       Impact factor: 13.501

4.  Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.

Authors:  Alicia M Mihaliak; Candace A Gilbert; Li Li; Marie-Claire Daou; Richard P Moser; Andrew Reeves; Brent H Cochran; Alonzo H Ross
Journal:  Cancer Lett       Date:  2010-10-28       Impact factor: 8.679

Review 5.  Stem cell glycolipids.

Authors:  Makoto Yanagisawa
Journal:  Neurochem Res       Date:  2010-12-16       Impact factor: 3.996

6.  Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression.

Authors:  David Kozono; Jie Li; Masayuki Nitta; Oltea Sampetrean; David Gonda; Deepa S Kushwaha; Dmitry Merzon; Valya Ramakrishnan; Shan Zhu; Kaya Zhu; Hiroko Matsui; Olivier Harismendy; Wei Hua; Ying Mao; Chang-Hyuk Kwon; Hideyuki Saya; Ichiro Nakano; Donald P Pizzo; Scott R VandenBerg; Clark C Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-09       Impact factor: 11.205

Review 7.  Chemotherapy targeting cancer stem cells.

Authors:  Haiguang Liu; Lin Lv; Kai Yang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

8.  Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex.

Authors:  Hacer Guvenc; Marat S Pavlyukov; Kaushal Joshi; Habibe Kurt; Yeshavanth K Banasavadi-Siddegowda; Ping Mao; Christopher Hong; Ryosuke Yamada; Chang-Hyuk Kwon; Deepak Bhasin; Somsundaram Chettiar; Gaspar Kitange; In-Hee Park; Jann N Sarkaria; Chenglong Li; Mihail I Shakhparonov; Ichiro Nakano
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

9.  PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.

Authors:  R Auvergne; C Wu; A Connell; S Au; A Cornwell; M Osipovitch; A Benraiss; S Dangelmajer; H Guerrero-Cazares; A Quinones-Hinojosa; S A Goldman
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

10.  Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines.

Authors:  Marie-Claude Amoureux; Béma Coulibaly; Olivier Chinot; Anderson Loundou; Philippe Metellus; Geneviève Rougon; Dominique Figarella-Branger
Journal:  BMC Cancer       Date:  2010-03-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.